Clinical Trials Browser

Ivermectin × Breast × 90 days × Clear all

NCT05318469 2026-05-06

Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer

Phase 1/2 Recruiting

Triple Negative Breast Neoplasms